Regeneron Pharmaceuticals
REGN
473 hedge funds and large institutions have $25.8B invested in Regeneron Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 141 increasing their positions, 203 reducing their positions, and 33 closing their positions.
100% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 33
21% more capital invested
Capital invested by funds: $21.3B → $25.8B (+$4.52B)
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
6% more funds holding
Funds holding: 447 → 473 (+26)
31% less repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 203
35% less call options, than puts
Call options by funds: $378M | Put options by funds: $580M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$230M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$156M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$150M |
| 4 |
Polen Capital Management
Boca Raton,
Florida
|
+$115M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$76.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$631M |
| 2 |
Goldman Sachs
New York
|
-$264M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$209M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$112M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$102M |
REGN Hedge Fund Activity: Q3 2014 in Review
473 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2014, worth a combined $25.8B — up 21% from $21.3B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new REGN positions and 33 closed out — a net gain of 33 holders — while 141 added to existing stakes and 203 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was Viking Global Investors, cutting an estimated $631M.
- 473 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2014, up from 447 in Q2 2014.
- Funds reported $25.8B of Regeneron Pharmaceuticals stock for Q3 2014, up 21% quarter-over-quarter.
- 66 funds opened new Regeneron Pharmaceuticals positions in Q3 2014 and 33 closed out, a net change of +33 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $230M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2014 was Viking Global Investors, an estimated $631M sold.
Based on aggregated 13F filings for Q3 2014.